

**Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab)  
Recombinant Antibody  
Catalog # APR10097****Specification****Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Product Information**

|                   |                            |
|-------------------|----------------------------|
| Application       | FC, Kinetics, Animal Model |
| Primary Accession | <a href="#">P32970</a>     |
| Reactivity        | Human                      |
| Clonality         | Monoclonal                 |
| Isotype           | IgG1                       |
| Calculated MW     | 146.1 KDa                  |

**Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Additional Information****Target/Specificity**

TNFSF7 / CD27L / CD70

**Endotoxin**

&lt; 0.001EU/ µg,determined by LAL method.

**Conjugation**

Unconjugated

**Expression system**

CHO Cell

**Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Protein Information****Name** CD70 ([HGNC:11937](#))**Function**

Expressed at the plasma membrane of B cells, it is the ligand of the CD27 receptor which is specifically expressed at the surface of T cells (PubMed:<a href="http://www.uniprot.org/citations/28011863" target="\_blank">28011863</a>, PubMed:<a href="http://www.uniprot.org/citations/28011864" target="\_blank">28011864</a>, PubMed:<a href="http://www.uniprot.org/citations/8387892" target="\_blank">8387892</a>). The CD70-CD27 signaling pathway mediates antigen-specific T cell activation and expansion which in turn provides immune surveillance of B cells (PubMed:<a href="http://www.uniprot.org/citations/28011863" target="\_blank">28011863</a>, PubMed:<a href="http://www.uniprot.org/citations/28011864" target="\_blank">28011864</a>).

**Cellular Location**


Cell membrane; Single-pass type II membrane protein

## Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


## Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) - Images




Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) is more than 99.29% ,determined by SEC-HPLC.



HL-60 cells were stained with Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC150=0.06731 µg/mL



The endocytosis ratio vorsetuzumab by 786-O increased with the increase of antibody concentration, and the Internalization Rate (%) reached 55% at antibody concentration of 0.67 nM.